Davita Inc vs Wendys Co — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Wendys Co trades at $6.22 (market cap $1.16B). The key difference: Davita Inc is far larger — about 9.7× Wendys Co's market cap, and Wendys Co pays a 4.59% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Wendys Co for 77 Days on average.
| DVA | WEN | |
|---|---|---|
Market Cap | $11.28B | $1.16B |
Volume | 650,294 | 4,715,639 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $9.33 |
52-Week Low | $103.87 | $6.10 |
Typical Hold Time | 113 Days | 77 Days |
Enterprise Value | $24.00B | $4.90B |
Dividend Yield | — | 4.59% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Wendy's (WEN) trades at $6.22, up 0.97% today but remains under significant pressure with a bearish technical outlook. The stock shows attractive valuation metrics including a P/E of 9.25 and P/S of 0.53, though fundamentals reveal declining profitability with net income margin dropping to 5.72% in 2025. Recent news highlights challenges including a major franchisee bankruptcy filing and six consecutive quarters of same-store sales declines, creating headwinds for the burger chain.
Despite low valuations and consistent earnings beats, Wendy's faces substantial operational challenges including franchisee instability and competitive pressures. The consensus price target of $7.58 suggests 22% upside potential, but investor sentiment remains cautious given the deteriorating fundamentals and bearish technical signals. Recovery depends on successful execution under new CEO Bob Wright and reversing negative sales trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →